Abstract library

13 results for "hypercalcemia".
#810 Pancreatic Neuroendocrine Tumor Presenting in Pregnancy with Severe Hypercalcemia
Introduction: Malignant hypercalcemia secondary to pancreatic neuroendocrine tumor (pNET) is a rare occurrence with no standard management. We report a challenging case of pNET presenting during pregnancy and complicated by severe hypercalcemia.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: MD Rita E Assi
#2212 A Rare Case of Paraneoplastic Hypercalcemia Secondary to a Neuroendocrine Pancreatic Tumour (pNET).
Introduction: Paraneoplastic hypercalcemia (HC) is a well-described affection in literature. It can relay on several mechanisms among with bone osteolysis, Parathormone (PTH) related peptide (rp) production, primary hyperparathyroidism, and Calcitriol (CT) secretion. CT secretion-mediated HC is more frequently observed among lymphomas and has only been once reported in pNET.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Dr. Aïmen Belaïd
Authors: Belaïd A, Dhenin A, Jopart P, Seront E, ...
#981 Parathyroid Hormone-Related Peptide (PTHrP) Secretion by Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET): Clinical Features, Diagnosis, Management, and Long-Term Follow-Up
Introduction: There are a few large series of patients with parathyroid hormone (PTH)-related protein (PTHrP) secreting neuroendocrine tumors (NETs) causing severe hypercalcemia.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Drs Kimberly Kamp
Keywords: PTH, PTHrP, net, hypercalcemia
#1014 Sunitinib Induced Hypocalcaemia During Treatment of Pancreatic Neuroendocrine Tumors (pNETs)
Introduction: Sunitinib is an oral multitargeted tyrosine kinase inhibitor used for pNET treatment.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Krystallenia Alexandraki
#236 Very Long-term Follow-up (> 5 years) of Renal Function of Neuroendocrine Tumor Patients Treated with Five or More Cycles of Peptide Receptor Radionuclide Therapy (PRRNT)
Introduction: Nephrotoxicity is one of the primary concerns in neuroendocrine tumor (NET) patients (pts.) treated with peptide receptor radionuclide therapy (PRRNT).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
#559 The Bone Scintigram in Patients with Neuroendocrine Tumors - A Series of 12 Cases
Introduction: The bone metastasis finding is based on imaging or aggressive features as high Ki-67 or rapidly progressive disease.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Mara Carsote
Keywords: neuroendocrine, bone
#723 The Calcium Metabolism Disturbances 40 Patients with Neuroendocrine Tumors: A Cross-Sectional Study
Introduction: Bone diseases associated with NET are due to genetic background, NET evolution, or they are incidental.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Prof. Catalina Poiana
Authors: Poiana C, Carsote M, Dusceac R, Muler M, ...
Keywords: PTH, calcium
#736 The Bone Metastasis Phenotype in Patients Diagnosed with Neuroendocrine Tumors
Introduction: Bone metastasis (BM) is actively searched especially in patients (p) with a long history of NET.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Catalina Poiana
Authors: Carsote M, Ene C, Popescu M, Petris R, ...
#968 An Early Rare MEN1 Phenotype
Introduction: A 13-yr-old boy was referred to our department for short stature.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Marialberta Battocchio
Keywords: MEN1, hypercorticism
#1267 Two Cases of Parathyroid Cancer with Pulmonary Metastasis
Introduction: Parathyroid cancer(PC) is a rare disease accounting for less then 1% of all patients with primary hyperparathyroidism. The prognosis of patients with parathyroid carcinoma is variable; more than 50% have a persistent or recurrent disease due to a regional or distant disease.
Conference: 13th Annual ENETS conference (2016)
Category: Pathology, grading, staging
Presenting Author: Iya Voronkova